Heterotopic Ossification Following Spinal Cord Injury

Peiwen Cao MSc
Fatima Alibrahim MD
Amanda McIntyre PhD (c) RN
Swati Mehta PhD
Eldon Loh MD FRCPC
Robert Teasell MD FRCPC
Key Points

Anti-inflammatory medications given early post-spinal cord injury reduces development of heterotopic ossification.

Warfarin may inhibit the development of heterotopic ossification post-spinal cord injury.

Alendronate does not prevent the development of heterotopic ossification and may cause contractures.

Etidronate may be effective for halting the progression of heterotopic ossification when administered early.

Pamidronate halts secondary progression of heterotopic ossification post-surgical excision.

Pulse low intensity electromagnetic field therapy is effective in preventing heterotopic ossification post spinal cord injury.

Radiotherapy can reduce the progression and recurrence of heterotopic ossification.

Surgical resection of heterotopic ossification can improve hip range of motion but it may recur in a large number of individuals.

Surgical resection and pamidronate treatment halts secondary heterotopic ossification progression.

This review has been prepared based on the scientific and professional information available in 2021. The SCIRE project is provided for informational and educational purposes only. If you have or suspect you have a health problem, you should consult your health care provider. The SCIRE editors, contributors and supporting partners shall not be liable for any damages, claims, liabilities, costs, or obligations arising from the use or misuse of this material.


www.scireproject.com
Table of Contents

10 Executive Summary ........................................................................................................................................... 1
2.0 Introduction ...................................................................................................................................................... 2
3.0 Pathophysiology of Heterotopic Ossification ................................................................................................. 2
4.0 Risk Factors and Clinical Presentation ........................................................................................................... 4
5.0 Diagnosis .......................................................................................................................................................... 6
6.0 Interventions for Heterotopic Ossification ........................................................................................................ 7
   6.1 Non-Steroidal Anti-Inflammatory Drugs as Prophylaxis .............................................................................. 9
   6.2 Warfarin as Prophylaxis .................................................................................................................................. 11
   6.3 Bisphosphonates ........................................................................................................................................... 12
   5.4 Pulse Low Intensity Electromagnetic Field (PLIMF) Therapy ................................................................. 16
   5.5 Radiation Therapy ........................................................................................................................................ 17
   5.6 Surgical Resection ......................................................................................................................................... 20
6.0 Summary .......................................................................................................................................................... 25
7.0 References ......................................................................................................................................................... 27
Abbreviations .......................................................................................................................................................... 31

This review has been prepared based on the scientific and professional information available in 2021. The SCIRE project is provided for informational and educational purposes only. If you have or suspect you have a health problem, you should consult your health care provider. The SCIRE editors, contributors and supporting partners shall not be liable for any damages, claims, liabilities, costs, or obligations arising from the use or misuse of this material.


www.scireproject.com
Heterotopic Ossification Following Spinal Cord Injury

10 Executive Summary
Heterotopic ossification (HO) is the formation of pathological bone in muscle or soft tissue (Shehab, Elgazzar & Collier, 2018). The incidence in individuals following a spinal cord injury (SCI) has been reported to vary greatly, ranging from 10% to 78% (Banovac 2001; van Kuijk et al. 2002, Ranganathan et al. 2015). HO occurs most frequently in the first two months after SCI, below the level of paralysis (Banovac et al. 2001) and most commonly forms in the hip but rarely the peripheral joints (Ranganathan et al. 2015). The mechanism underlying HO following spinal cord injury is not fully understood creating challenges in early diagnostic and therapeutic interventions.

What are the clinical symptoms of Heterotopic Ossification following injury?

<table>
<thead>
<tr>
<th>Risk Factors for HO (Citak et al. 2012; Krauss et al. 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Complete neurological deficit</td>
</tr>
<tr>
<td>• Spasticity</td>
</tr>
<tr>
<td>• Pneumonia</td>
</tr>
<tr>
<td>• Thoracic trauma</td>
</tr>
<tr>
<td>• Tracheostomy</td>
</tr>
<tr>
<td>• Nicotine use</td>
</tr>
<tr>
<td>• Urinary tract infection</td>
</tr>
<tr>
<td>• Less comorbidities</td>
</tr>
<tr>
<td>• Hyper-coagulable states</td>
</tr>
<tr>
<td>• Deep vein thrombosis (DVT)</td>
</tr>
<tr>
<td>• Pulmonary embolism (PE)</td>
</tr>
</tbody>
</table>

Evaluation of preceding factors, in combination with early intervention and diagnosis, may reduce incidence of HO or improve a patient’s recovery post-operatively (Citak et al. 2012).

Clinical symptoms of HO being to appear 3-12 weeks post injury (Schuetz et al. 2005), and include: joint and muscle pain, paraesthesias and tissue swelling in the involved region, accompanied by a mild fever (Thomas & Amstutz 1987; Orzel & Rudd 1985; Smith 1998; Shehab et al. 2002), while some SCI patients do not experience any pain.

How is Heterotopic Ossification diagnosed?

**Triple phase bone scanning**: More sensitive, but less specific than plain radiography in detecting early HO (Freed et al. 1982).

**Plain Radiography**: Can detect neurogenic HO 2-6 weeks after diagnosis using triple phase bone scan (Orzel et al. 1985; Freed et al. 1982).

**Computed tomography (CT) or Magnetic Resonance Imaging (MRI)**: Better visualization of heterotopic bone (Amendola et al. 1983); useful when considering surgery.

**Biochemical Markers**: Used to evaluated elevations in alkaline phosphatase and creatine phosphokinase, however value has not been validated (Singh et al. 2003; Welch et al. 1973; Rossier et al. 1973).

**Brooker Classification Scheme**: Typically used to diagnose HO in the pelvic region using anteroposterior radiograph of the pelvis which classifies HO into one of five classes (Zychowicz 2013). Has been criticized by some clinicians, as it cannot be used to determine the potential drawbacks of surgery and gives pessimistic results of hip range of motion with some hips classified as III or IV despite no clinical ankylosis found.
What management options are there for Heterotopic Ossification?

Non-steroidal anti-inflammatory medications: Indomethacin and Rofecoxib have both been evaluated in the treatment of HO post SCI, however Rofecoxib is no longer available due to cardiovascular side effects (Banovac et al. 2001).

Anticoagulants: Warfarin may be useful in the prevention of HO post SCI (Buschbacher et al. 1992).

Bisphosphonates: Alendronate had no direct correlation for prevention of HO and may cause contractures (Ploumis et al. 2015). Etidronate was shown in several studies to halt the progression of HO (Garland et al. 1983; Banovac et al. 1993; Banovac et al. 1997; Stover et al. 1987). Pamidronate effectively halts secondary prevention of HO after surgical resection of heterotopic ossification (Schuetz et al. 2005).

Pulse Low Intensity Electromagnetic Field Therapy: Effective in preventing HO post-spinal cord injury (Durovic et al. 2009).

Radiation Therapy: Although the evidence is limited, studies show that radiotherapy reduces the progression of HO (Sautter-Bihl et al. 2000; Sautter-Bihl et al. 2001).

Surgical Resection: Can improve hip range of motion but recurrence and complications are of concern (Genet et al. 2011; Garland & Orwin 1989; Meiners et al. 1997).

Gaps in the Evidence

- Mechanism of action of NSAIDs in preventing the occurrence of HO
- The role of NSAIDs once the patient starts to develop symptoms with or without radiographic evidence of HO
- Optimal criteria for decisions regarding excision

2.0 Introduction

Heterotopic ossification (HO) is the formation of pathological bone in muscle or soft tissue (ref). The incidence in individuals following a spinal cord injury (SCI) has been reported to vary greatly, ranging from 6.3% to 78% (Banovac 2001; van Kuijk et al. 2002, Ranganathan et al. 2015; Rawat et al., 2019; Ung et al., 2020). HO occurs most frequently in the first two months after SCI, below the level of paralysis (Banovac et al. 2001) and most commonly forms in the hip but rarely in the peripheral joints such as the elbows and knees (Ranganathan et al. 2015; Rawat et al., 2019).

3.0 Pathophysiology of Heterotopic Ossification

The mechanism underlying HO following spinal cord injury is not fully understood creating challenges in early diagnostic and therapeutic interventions. In the body, bone tissues are maintained by three primary cell types; osteoblasts, osteocytes, and osteoclasts (Findlay, 2018). HO appears to be initiated by metaplasia of mesenchymal cells into bone precursor cells (Schuetz et al. 2005). Mesenchymal stem cells can differentiate into osteogenic cells given the right stimuli and within the right
environment (even soft tissue; Chalmers et al. 1975; Pape 2004). These mesenchymal stem cells can generate cartilage, muscles, tendons, ligaments or fat, besides bone (Williams et al. 1999) and are thought to play a pivotal role in the development of HO (Pape et al. 2004). After mesenchymal cell differentiation to osteogenic cells, a protein mixture created by bone cells (osteoid) calcifies within a matter of weeks (Pape et al. 2001). Over the next few months, the calcified osteoid remodels and matures into well-organized trabecular bone (Pape et al. 2001). Months following the initial trauma, patients develop bone formation in muscle and soft tissues in an ectopic location with resultant restriction in range of motion, pain and ankyloses at the affected joint (Banovac & Gonzalez 1997; Garland et al. 1980). The bony lesion has a high metabolic rate, adding new bone at more than three times the rate of normal bone. Osteoclastic (bone removal cells) density is more than twice that found in healthy bone (Puzas et al. 1987). It is suspected there may be a neurogenic factor contributing to HO but the mechanism is poorly understood (Hurvitz et al. 1992; Pape et al. 2001; Pape et al. 2004).

Another recent theory for the development of HO has been suggested (Brady, Shultz, McDonald & O’Brien, 2018). As an inflammatory response is triggered by CNS damage, the inflammatory cells involved, such as neutrophils, lymphocytes, and macrophages, are thought to release a variety of growth factors and cytokines (Tannous et al., 2013). These inflammatory lesions are thought to eventually turn into bone through a hypoxic microenvironment ultimately leading to mesenchymal condensations at peripheral injury sites (Wang et al., 2016; Agarwal et al., 2016; Winkler et al., 2015).
4.0 Risk Factors and Clinical Presentation

A case-control study was performed by Citak et al. (2012) among 132 individuals with traumatic spinal cord injury and 132 controls to determine risk factors for HO. The authors reported that the presence of complete neurological deficit was a major risk factor for HO. Moreover, factors such as spasticity, pneumonia, thoracic trauma, tracheostomy, nicotine use, and urinary tract infection increase patients’ risk for HO (Citak et al. 2012; Yolcu et al., 2020a). However, another study has reported that patients with fewer comorbidities are also at a higher risk for developing HO. The evaluation of the preceding factors, in combination with early intervention and diagnosis, may reduce incidence of HO or improve a patient’s recovery post-operatively (Citak et al. 2012).

Figure 1 Mechanism for development of heterotopic ossification
Gender and injury severity have been associated with the likelihood of developing HO following SCI (Krauss et al., 2014; Yolcu et al., 2020a). Specifically, Krauss et al. (2014) reported that males were five times more likely to develop HO compared to their female counterpart. In addition, a case series and a recent meta-analysis showed that patients with complete SCI were at greater risk of developing HO than those with incomplete SCI (Krauss et al., 2014; Yolcu et al., 2020a). Level of injury as a risk factor was highlighted by Ranganathan et al. (2015) whose literature review revealed that injuries to the thoracic and cervical spine are greater risk of developing HO. However, it should be noted both gender and injury severity as risk factors have been disputed in the literature (Krauss et al., 2014).

Krauss et al. (2014) also investigated the role of hyper-coagulable states and related blood markers as risk factors in the development of HO. D-Dimer was elevated in 24 out of 32 patients with SCI and concurrent HO. Following this, the role of deep vein thrombosis (DVT) and pulmonary embolism (PE) have also been linked to the development of HO. Reznik et al. (2014) reported that DVT/PE were significant predictors of HO along with multiple pressure ulcers and AIS B severity score. Reznik et al. (2014) propose that the association of HO and DVT/PE is due to the link between trauma/surgery/fractures and stimulation/increase in thrombogenic factors such as thromboplastin or factor III. The association between DVT and HO, however, was not identified in the meta-analysis by Yolcu et al. (2020a) examining current evidence on risk factors associated with HO post-SCI.

The link between the presence of pressure ulcers and development of HO in the SCI population has also been shown in a case series by Rawat et al. (2019). The relationship between HO and pressure ulcers is thought to be due to pressure ulcer infection deep enough to reach the bone. Along with tissue hypoxia, prolonged immobilization and muscle trauma, these factors combine to increase the risk of HO formation (Emami Razavi et al., 2015). Further research is required to solidify the relationship between HO and pressures sores/ulcers.

An observational study by McKean et al. (2021) evaluated pelvic magnetic resonance imaging muscle signal changes and their association with early HO in 40 patients within the first six months post-SCI. The findings demonstrated that increased T2 muscle signal was common following SCI and was linked to early MR signs of HO among patients.

Recently, a number of studies have also examined potential biological factors that contribute to the development of neurogenic heterotopic ossification (Egan, Duque, Keenan & Pignolo, 2018; Povoroznyuk, Bystrytska, Balatska, 2017). A study by Egan et al. (2018) evaluated the presence of circular osteogenic precursor cells (COP bone marrow-derived type 1collagen+CD45+) in incidences of non-hereditary HO. All tissue samples collected revealed the presence of COP cells. As these hematopoietic-derived cells were shown to both migrate to inflammatory sites and have osteogenic potential, there is the possibility to use COP cell count as an indicator of the risk for HO development post-SCI (Egan et al., 2018). Another study by Povoroznyuk et al. (2017), identified that the serum marker procollagen type 1N-terminal propeptide (P1NP) for bone formation was the specific bone turnover
marker implicated in HO formation. It was concluded that concentrations of 187.3 ng/mL or higher could be used as an early indicator of HO (Povoroznyuk et al., 2017).

Between 3-12 weeks, symptoms of HO start to appear (Schuetz et al. (2005). The initial clinical signs of inflammation are non-specific for HO (Neal 2003). Individuals typically present with joint and muscle pain, paraesthesias and tissue swelling in the involved region, accompanied by a mild fever (Thomas & Amstutz 1987; Orzel & Rudd 1985; Smith 1998; Shehab et al. 2002), and a possible reduction in mobility at the HO site (Brady et al., 2018). Conversely, some SCI patients do not experience any pain. Skeletal bio-markers can help detect development of HO, in particular, ALP serum, CPK, C-reactive protein, prostaglandin E2, and erythrocyte sedimentation rate which have been associated with HO after SCI (Ploumis et al. 2015).

5.0 Diagnosis

In the early phase of HO, triple phase bone scanning demonstrates increased uptake of osteotropic radionucleotides. Bone scanning has proven to be more sensitive than plain radiography in detecting early HO. Neurogenic HO becomes evident on plain radiography approximately two to six weeks after diagnosis using the triple phase bone scan (Orzel et al. 1985; Freed et al. 1982). However, bone scans have lower specificity than radiography (Freed et al. 1982). Computed tomography (CT) or magnetic resonance imaging (MRI) scanning may be a useful tool when considering surgery as it allows for better visualization of the heterotopic bone (Amendola et al. 1983). A recent study has also shown that ultrasound can be an effective diagnostic tool for early HO detection (Rosteius et al., 2017). Of 217 patients with confirmed HO on CT, signs of HO were correctly noted in 193 (88.9%) patients with SCI three weeks earlier via ultrasound (Rosteius et al., 2017).

Some studies have examined diagnosis of HO through elevations in biochemical markers such as alkaline phosphatase (Singh et al. 2003; Tibone et al. 1978) and creatine phosphokinase (Singh et al. 2003; Welch et al. 1973; Rossier et al. 1973). The predictive value of alkaline phosphatase has not been validated (Singh et al. 2003; Welch et al. 1973; Rossier et al. 1973), although there is conflicting evidence of an association with HO and increased serum creatine phosphokinase levels (Singh et al. 2003; Welch et al. 1973). Schurch et al. (1997) studied individuals with acute SCI and found increases in urine 24-hour prostaglandin E2 (PGE2) a valid indicator of early HO formation.

The Brooker Classification Scheme is typically used to diagnose HO in the pelvic region (Zychowicz 2013). The system is based on an anteroposterior radiograph of the pelvis which classifies HO into one of five classes. The classes are based on the progression of ossification: Class 0 – no presence of ossification, Class 1- islands of bone within soft tissue of any size, Class 2 - bone spurs from pelvis or femur with at least one cm between opposing bone surfaces, Class 3 - bone spurs from pelvis and femur reducing space between opposing bone surfaces to less than 1cm, and Class 4 - complete ankylosis of hip (Zychowicz 2013).
The Brooker Classification Scheme has been criticized by some clinicians and adjustments to the traditional classification system have been proposed. Mavrogenis et al (2012) have suggested focusing on the location of the HO formation around the hip joint using the following scheme: Type 1–anterior, Type 2–posterior, Type 3–anteromedial, Type 4–circumferential HO. The adjustments are based on describing the anatomical position of HO, which could permit an estimate of blood loss, transfusion requirements, and recurrence. The new classification system improves ease of use and provides the opportunity for more rapid post-operative planning of surgical approach, evaluation, and prognosis (Mavrogenis et al. 2012). However, Citak et al. (2012) suggested the use of ultrasound, CT or MRI rather than radiographs in order to improve diagnosis and to reduce the use of methods with less sensitivity for early diagnosis.

A new classification has been proposed by Arduini et al. (2015) based on the use of a 3D-CT reconstruction scan. The authors propose that this method allows the surgeon to observe the bone bridge in its entirety, can assist in assessing the relationship between neurovascular structures and the HO, and can identify the site of discontinuity, allowing the surgeon to plan the best surgical approach. Arduini et al. (2015) contend that their approach is more advantageous in comparison to the Brooker Classification, which they believe is inadequate at classifying the anatomy of the HO, and Mavrogenis et al. (2012)’s proposal, which the authors argue cannot give precise details regarding the continuity of the bone bridge or the extent to which surrounding muscles and soft-tissues are being affected. Genêt et al. (2015) also highlight that the Brooker Classification cannot be used to determine the potential drawbacks of surgery and gives pessimistic results of hip range of motion post-operatively with some hips classified as III or IV despite no clinical ankylosis found. Arduini et al. (2015) state that their classification system has reproducible high intra- and inter-observer reliability and that previous methods including Garland’s radiological classification and Mavrogenis et al. (2012) CT approach have not been validated. However, it is also important to note that Arduini et al. (2015) used a mixed population of SCI and TBI with SCI accounting for 29% of the sample. Although their approach is of interest, further research is required with an all-SCI, or at least SCI-majority, group of patients.

### 6.0 Interventions for Heterotopic Ossification

The published literature on treatment of HO provides evidence for non-steroidal anti-inflammatory drugs, warfarin, bisphosphonates, pulse low-intensity electromagnetic field therapy, radiation and surgical excision.

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Country</th>
<th>Date included in the review</th>
<th>AMSTAR score</th>
<th>Number of articles</th>
<th>Method: Level of evidence Questions</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yolcu et al. 2020b USA</td>
<td>Method: Comprehensive literature search of English RCT and</td>
<td>1</td>
<td>Overall incidence of HO was 9.73% in the medication group</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Review and meta-analysis of published articles until December 20, 2018 (N=5) observational studies directly comparing prophylactic medication to a placebo for prevention of HO following SCI in adult age group (≥18 yr). A meta-analysis comparing the incidence of HO between the two groups was conducted, with a subgroup analysis of non-steroidal anti-inflammatory drugs (NSAIDs) and non-NSAIDs.

**Databases:** EBM, Embase, Ovid Medline, Scopus, Web of Science

**Level of Evidence:** According to the Cochrane Collaboration for assessing risk, the two RCTs showed low risk. The observational studies scored between 7–8 on the Newcastle-Ottawa Scale (NOS), indicating high quality of evidence. Confidence in estimates was high for both overall HO and NSAIDs subgroup, while non-NSAIDs was ranked low due to inconsistency in reporting as well as the large CI.

**Questions/measures/hypothesis:**
1. Assess the preventive efficacy of prophylactic medications on heterotopic ossification after SCI compared to placebo.
2. In the subgroup analysis for NSAIDs, those who received prophylactic treatment with NSAIDs had a lower incidence of HO compared to those who received placebo (p=0.003).
3. As for studies that used bisphosphonates, a significant difference in incidence of HO was not found (p=0.58) and the overall evidence was inconclusive.

**Aubut et al. 2011**
**Canada**

Review of published articles between 1980-2010 (AMSTAR=8, N=26)

**Method:** Comprehensive literature search of English RCT, Cohort studies, case series, and review articles of traumatic SCI in adult age group (≥18 yr).

**Databases:** MEDLINE, EMBASE, CINAHL, PsycInfo.

**Level of evidence:**
- Moderate quality: Downgraded high quality studies, non-randomized trials, prospective cohort studies
- Low quality: Retrospective observational, retrospective cohort and case-control studies
- Very low quality: Case series, case reports, reviews and others

**Questions/measures/hypothesis:**
1. Examine the effectiveness of pharmacological, non-pharmacological and surgical management of HO after ABI and SCI.
2. ABI population usually required multicomponent treatments compared to the SCI population.
3. There are more level 1 and level 2 evidence for the SCI literature in supporting HO treatment, while the literature for the ABI population is weaker with mainly level 4 evidence.
4. HO in SCI patients was mostly seen in the hip while the ABI patients had more varied location of HO including hip, knee and elbow.

**Teasell et al. 2010**
**Canada**

Review of published articles between 1980-2009 (AMSTAR=8)

**Method:** Comprehensive literature search of English RCT, Cohort studies, case series, and review articles of traumatic SCI in adult age group (≥18 yr).

**Databases:** MEDLINE, EMBASE, CINAHL, PsycInfo.

1. There was strong evidence that early prophylactic treatment was efficacious in preventing HO, in which NSAIDs showed greatest effectiveness (level 1 evidence).
Questions/measures/hypothesis: Examine the effectiveness of pharmacological, non-pharmacological and surgical management of HO after SCI.

Three systematic reviews examined the effectiveness of HO management interventions. Aubut et al. (2011) found that pharmacological interventions were effective in the prophylaxis of HO. Teasell et al. (2010) also found that rofecoxib and indomethacin were effective in preventing HO after SCI. However, only limited evidence supported the use of radiotherapy, warfarin, or Pulse low intensity electromagnetic field therapy (PLIMF) for the prevention of HO after SCI. Once HO developed, only surgical resection was found to be effective, while bisphosphonates such as Etidronate Disodium and pamindronate were supported by limited evidence. Finally, Yolcu et al. (2020b) conducted a systematic review and meta-analysis comparing prophylactic medications to placebo for prevention of HO post-SCI. Although the overall analysis did not indicate a statistically significant benefit to use of prophylactic medication to prevent HO as compared to placebo, when only analyzing NSAIDs, patients who received prophylactic NSAIDs showed significantly lower incidence of HO. The authors pointed out that while promising for secondary prevention of HO among patients with SCI, further prospective studies with longer follow-ups are needed to explore other appropriate medications for HO prevention (Yolcu et al., 2020b).

6.1 Non-Steroidal Anti-Inflammatory Drugs as Prophylaxis

Indomethacin and Rofecoxib have been evaluated in the treatment of HO post SCI.

Table 2. Anti-Inflammatory Drugs as a Prophylaxis for Heterotopic Ossification

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>Research Design</th>
<th>Study Score</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banovac et al. 2004</td>
<td>USA</td>
<td>RCT</td>
<td>PEDro=10</td>
<td>N=76</td>
<td>Population: Gender: males=65, females=11; Severity of injury: complete, incomplete, AIS: A-C; Mean time since injury: 24 days.</td>
<td>1. A significantly lower incidence of HO was found in the rofecoxib group (13.4%) than in the placebo group (33.3%, p&lt;0.05). 2. In patients receiving rofecoxib, there was 2.5x lower relative risk of developing HO than in the placebo group.</td>
</tr>
<tr>
<td>Banovac et al. 2001</td>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td>Population: Mean age: 33 yr; Gender: males=33, females=0;</td>
<td>1. There was a significantly higher incidence of early HO,</td>
</tr>
<tr>
<td>RCT</td>
<td>PEDro=9</td>
<td>N=33</td>
<td>Severity of injury: AIS: A-D; Groups: treatment=16, placebo=17. <strong>Intervention:</strong> Slow-release indomethacin 75 mg daily versus placebo x3/wk. Patients were followed up clinically until they showed signs and symptoms of HO; all were followed up with x-rays at 2 mo and 6 mo. Where patients had a positive bone scan for HO, the study was D/C and patient was initiated on Etidronate Disodium. <strong>Outcomes Measures:</strong> The effect of indomethacin administration on the incidence of HO.</td>
<td>diagnosed on bone scan, in the placebo group (11/17) than in the group taking indomethacin (4/16) (p&lt;0.001). 2. In the placebo group, 7/17 patients developed x-ray evidence of HO as did 2/16 in the indomethacin treated group (p&lt;0.001).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Population:** | **NSAID prophylaxis Group (n=27):** Mean age: 31yr; Gender: males=23, females=4; Level of injury: paraplegia=12, tetraplegia=15; Severity of injury: ASIA A=24, B=3; Time since injury: ≤60 d. **No prophylaxis Group (n=81):** Mean age: 37 yr; Gender: males=64, females=17; Level of injury: paraplegia=29, tetraplegia=52; Severity of injury: ASIA A=55, B=26; Time since injury: ≤60d. **Intervention:** A retrospective chart review of all patients consecutively admitted to the SCI acute rehabilitation program at Santa Clara Valley Medical Center between October 2013 and March 2017. The NSAID prophylaxis group received ≥ 15 days of non-steroidal anti-inflammatory drug (NSAID) therapy (overall range 6–44 days; indomethacin 75 mg sustained release once daily or 25 mg immediate release 3x / day, or celecoxib 200 mg once daily). The no prophylaxis group did not receive NSAID prophylaxis. **Outcome Measures:** Occurrence of HO, UTI during hospitalization, tracheostomy, inpatient rehabilitation length of stay and adverse event data including rates of bony non-union and gastrointestinal (GI) bleeding. | 1. Two individuals receiving ≥ 15 days of NSAID prophylaxis (24 days each) were diagnosed with HO (7.4%), compared with the 29 cases of HO diagnosed in the 81 people who did not receive prophylaxis (35.8%; p=0.006). 2. Significant predictors of HO diagnosis were tracheostomy (odds ratio (OR) 2.8, 95% confidence interval (CI) 1.1 to 7.5, p=0.039), pressure injury during hospitalization (OR 3.3, 95% CI 1.1 to 9.5, p=0.030), UTI during hospitalization (OR 4.3, 95% CI 15 to 12, p=0.006). 3. Length of stay was significantly longer in those who were diagnosed with HO compared with individuals not diagnosed with HO (p=0.008). 4. Adverse effects of NSAID use were minimal. | Two highly rated RCTs examined the use of non-steroidal anti-inflammatory drugs in the early phase after SCI in an attempt to reduce the incidence of HO. Banovac et al. (2001) randomized 33 SCI patients approximately three weeks post SCI and treated them prophylactically with either slow-release indomethacin 75 mg daily or placebo for a total of three weeks. Patients were carefully followed with regular clinical follow-up and bone scans. There was a significantly higher incidence of HO,
diagnosed on bone scan and plain radiographs, in the placebo group when compared with the group receiving indomethacin (p<0.001). Banovac et al. (2004) randomized 76 patients in the early phase post SCI into either the intervention group (25 mg rofecoxib daily for two weeks) or a placebo group. A significantly lower incidence of HO was observed in the rofecoxib group (13.4%) than in the placebo group (33.3%; p<0.05). These findings are in line with that from a recent case control study, which demonstrated a significantly lower likelihood of developing HO during the acute phase post-SCI among patients who received ≥ 15 days of non-steroidal anti-inflammatory drugs therapy compared to those who did not receive non-steroidal anti-inflammatory drugs (Zakrasek et al., 2019). Although these three studies provided compelling evidence that anti-inflammatory drugs given prophylactically reduce the likelihood of developing HO post-SCI, Rofecoxib is no longer available due to cardiovascular side effects.

Conclusions

*There is strong Level 1a evidence (from two RCTs; Banovac et al. 2001; Banovac et al. 2004) and level 3 evidence (from one case control study; Zakrasek et al., 2019) that non-steroidal anti-inflammatory medications can reduce the incidence of heterotopic ossification when administered early after a spinal cord injury.*

Anti-inflammatory medications given early post spinal cord injury reduces development of heterotopic ossification.

### 6.2 Warfarin as Prophylaxis

Warfarin is a well-known anticoagulant which may also be useful in the prevention of HO post SCI.

#### Table 3. Warfarin as a Prophylaxis for Heterotopic Ossification

<table>
<thead>
<tr>
<th>Author Year Country</th>
<th>Research Design Score</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buschbacher et al. 1992 USA Observational N=227</td>
<td>Population: Age range: 17-75 yr; Gender: males=213, females=14; Severity of injury: complete, incomplete. <strong>Intervention:</strong> Patients treated with warfarin for a mean of 5.4 wk post SCI for deep vein thrombosis; no X-rays taken to rule out HO. HO, diagnostic tests done only if clinical signs were suggestive. <strong>Outcome Measures:</strong> Prevalence of HO.</td>
<td>1. Warfarin administration and development of HO were found to be significantly related (p&lt;0.01). 2. None of the patients treated with Warfarin (n=33) developed HO and none of the patients with HO (n=34) had been treated with Warfarin.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
diagnosed with HO; among the remaining 193 patients, 34 were diagnosed with HO but not one of these individuals had been treated with Warfarin. The authors speculated that Warfarin provided a protective or inhibitory effect against HO.

**Conclusion**

*There is Level 5 evidence (from one observational study; Buschbacher et al. 1992) that Warfarin inhibits the development of heterotopic ossification post spinal cord injury.*

Warfarin may inhibit the development of heterotopic ossification post spinal cord injury.

### 6.3 Bisphosphonates

Three bisphosphonates, Alendronate, Etidronate (didronel) and pamidronate, have been studied in the treatment of HO progression post SCI. Alendronate is a potent nitrogen-containing second generation bisphosphonate and is thought to primarily inhibit bone resorption, while having a small effect on remineralization and has been observed to reduce development of HO (Ploumis et al. 2015). Etidronate was introduced in the 1970s for the treatment of HO post SCI and is still commonly used today (Banovac et al. 1997; Fleisch 1991). Etidronate works by inhibiting the transformation of amorphous calcium phosphate into crystalline hydroxyapatite (Fleisch 1991; Fleisch et al. 1969; Banovac et al. 1997). Although commonly used, its efficacy in HO prophylaxis has been questioned (Fineman & Stover 1981). Pamidronate is a new generation nitrogen-containing bisphosphonate (Schuetz et al. 2005).

#### Table 4. Bisphosphonates for Treatment of Heterotopic Ossification

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>Research Design Score</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ploumis et al. 2015</td>
<td>USA</td>
<td>Prospective Controlled Trial</td>
<td>Population: Alendronate (ALN, N=125): Mean age: 40.6 yr; Gender: males=86, females=39. Non-ALN (N=174): Mean age: 44.2 yr; Gender: males=140, females=34.</td>
<td>1. No significant correlation between diagnosis of HO and ALN intake was found. 2. A significant correlation was found between HO appearance and alkaline phosphate (ALP) serum abnormality (p&lt;0.001). Further, normal ALP serum levels were significantly correlated with ALN intake (p&lt;0.05) whilst abnormal ALP serum levels was significantly correlated with no ALN intake. 3. Significantly more patients receiving ALN developed contractures (p&lt;0.001).</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Study Design</td>
<td>N</td>
<td>Age Range</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>--------------</td>
<td>---</td>
<td>-----------</td>
</tr>
<tr>
<td>Banovac et al. 1997</td>
<td>USA</td>
<td>Prospective Controlled Trial</td>
<td>46</td>
<td>16-55 yr</td>
</tr>
<tr>
<td>Banovac et al. 1993</td>
<td>USA</td>
<td>Prospective Controlled Trial</td>
<td>27</td>
<td>15-64 yr</td>
</tr>
<tr>
<td>Stover 1987</td>
<td>USA</td>
<td>Pre-Post</td>
<td></td>
<td>&gt;16 yr</td>
</tr>
<tr>
<td>Banovac 2000</td>
<td>Denmark</td>
<td>Case Series</td>
<td>40</td>
<td>Mean age: 23 yr</td>
</tr>
<tr>
<td>Subbarao et al. 1987</td>
<td>USA</td>
<td></td>
<td></td>
<td>29-43 yr</td>
</tr>
</tbody>
</table>
Case Series
N=5
(72 hr) and continued for a minimum of 3 mo. All patients underwent wedge resection at hip to permit free movement of hip in flexion. **Outcome Measures**: Effects of treatment.

Garland et al. 1983
USA
Case Series
N=14
Population: Mean age=25 yr; Gender: males=9, females=5; Injury etiology: SCI; Level of injury: cervical=6, thoracic=5; Severity of injury: complete=7, incomplete=2.

**Intervention**: Bisphosphonate treatment was administered for 2wk at 20 mg/kg/day and then for 2yr at 10 mg/kg/day.

**Outcome Measures**: Effectiveness of treatment and adverse effects.

1. 8/9 pretreatment patients had HO in 10 hips.
2. Post-treatment all patients showed evidence of HO.
3. Of the 9 minimal graded hips, only 1 stayed at the minimal grade, whereas others increased (5 mild, 3 moderate, 5 severe).
4. No adverse effects were observed.

Pamidronate

Schuetz et al. 2005
Switzerland
Case Series
N=7
Population: Age range: 47-68 yr; Gender: males=7, females=0; Injury etiology: SCI=7; Level of injury: thoracic=1, tetraplegia=2.

**Intervention**: All patients underwent excision surgery for removal of HO. Pamidronate was administered IV peri-op and post-op, starting at a dose level of 120 mg for the first 12 hr, gradually increasing for a total of 6-14 days.

**Outcome Measures**: Prevalence of HO.

No statistical results reported
1. None of the patients treated with pamidronate showed clinical, x-ray or lab signs of HO recurrence or new forming HO at 5-54 mo follow-up.

Alendronate

Ploumis et al. (2015) prescribed 70 mg per week of Alendronate to 125 SCI patients over a mean of 267 days. Development of HO was compared with 174 SCI patients who did not receive Alendronate. No direct correlation was found between prevention of HO and Alendronate intake; however, there appeared to be an indirect link between the two as abnormal alkaline phosphate (ALP) serum levels were significantly correlated in patients with HO whilst normal ALP serum levels were significantly correlated with Alendronate intake. Therefore, Alendronate may be effective in reducing one of the risk factors of developing HO rather than a direct prophylactic advantage. A potential drawback for the use of Alendronate was the finding that patients were more likely to develop contractures whilst taking the drug compared to patients who were not (Ploumis et al. 2015).

Etidronate

Several studies aimed to determine the effect of Etidronate on HO and the regimen of administration. Garland et al. (1983) assessed the effectiveness of Etidronate treatment on SCI patients with clinical signs of HO over a two-year period. Ossification appeared to plateau in only one of nine patients, while an increase in HO was reported to varying degrees in the remaining patients. Banovac (2000) studied
40 patients with SCI and HO, who were diagnosed early with positive bone scan but negative x-rays, and were treated with Etidronate (intravenous for three days, then oral for six months). Of the 40, 11 individuals (27.5%) developed radiographic evidence of HO 1.5-6.0 years post initiation of therapy.

Banovac et al. (1993) provided intravenous Etidronate for three-five days followed by oral Etidronate for six months to 27 patients with SCI following a diagnosis of HO; outcomes were compared to 11 SCI patients treated with only oral Etidronate Disodium for six months. After the initial intravenous therapy, 20 patients showed prompt reduction in swelling over the first 48 hours while seven patients had no change or an increase in swelling. Overall, treatment reduced swelling ($p<0.01$); there was no significant difference in effect between the intravenous and orally treated groups on HO.

Banovac et al. (1997) studied 46 patients (five excluded due to discontinuation of therapy) treated with three days of intravenous Etidronate Disodium followed by oral Etidronate for six months. Of the 33 patients with a positive bone scan but a negative x-ray for HO, five discontinued treatment and showed gradual progression of HO. In the remaining 28 patients, 22 had no x-ray evidence of HO while six developed HO on x-ray. Among 13 patients who had a positive bone scan and a positive x-ray for HO, progression of soft tissue ossification was inhibited by Etidronate in six of these patients, while the remaining seven did not respond to treatment and showed further progression of HO. In a more recent case series by Banovac in 2000, a study of 40 patients found that Etidronate was not effective at reducing incidences of HO. Of 40 patients, 11 developed radiographic evidence of HO from 15-6 years post treatment and 95% of cases had developed additional HO in different joints (Banovac, 2000).

Stover et al. (1987) conducted a pre-post trial of 87 adult SCI patients and found that there was no difference between patients treated with Etidronate Disodium for three months versus those receiving therapy for six months. However, those who received earlier treatment did better on x-rays. Secondary prevention of HO post surgical excision was examined by Subbarao et al. (1987, N=5). Subbarao et al. (1987) examined Etidronate treatment pre- and post-surgical hip wedge resection and found that patients still had severe restriction in their range of motion at follow-up.

**Pamidronate**

Schuetz et al. (2005) reported that pamidronate was administered pre- and post-surgical removal of HO among individuals with SCI and had no recurrences. It is important to note that sample sizes in both studies were small.

The lack of RCTs and variable treatment regimens make it difficult to form definitive conclusions. It appears that Etidronate is able to delay or inhibit HO progression once it is diagnosed and it tends to work better when given earlier after diagnosis.

**Conclusions**
There is Level 2 evidence (from one prospective controlled trial; Ploumis et al. 2015) that Alendronate does not inhibit the development of heterotopic ossification and in fact may contribute to the development of contractures.

There is conflicting Level 2 evidence (from two prospective controlled trials; Banovac et al. 1993; Banovac et al. 1997) and Level 4 evidence (from one case series; Branovac 2000) that Etidronate can stop the progression of heterotopic ossification once the diagnosis is made and prevent further HO sites.

There is Level 2 evidence (from one prospective controlled trial; Banovac et al. 1997) that Etidronate is not effective once radiographs are positive for HO.

There is Level 4 evidence (from one case series; Schuetz et al. 2005) that Pamidronate effectively halts secondary HO progression after surgical resection of HO.

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>Research Design</th>
<th>Score</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durovic et al. 2009</td>
<td>Italy</td>
<td>RCT</td>
<td>PEDro=6</td>
<td>N=29</td>
<td>Population: Age range: 18-45 yr. <strong>Intervention:</strong> Patients were randomly divided into experimental and control groups. Intervention group received 30 min pulse low intensity electromagnetic field therapy (PLIMF) therapy (25 Hz, 10 mT) for 4 wk, approximately 7 wk post SCI. <strong>Outcome measures:</strong> Incidence of HO, Brooker classification.</td>
<td>1. Significant differences were found in the incidence of HO between the treatment and control groups. 2. 33% of individuals in the control group had incidence of HO; 0 cases of HO in the treatment group. 3. Among control groups individuals with HO post intervention, 2 progressed grade 1 to grade 2, and 1to</td>
</tr>
</tbody>
</table>

5.4 Pulse Low Intensity Electromagnetic Field (PLIMF) Therapy

PLIMF therapy uses magnetic fields to increase oxygen levels and decrease toxic by-products of inflammation by increasing local blood flow (Durovic et al. 2009).

Table 5 Pulse Low Intensity for Treatment of Heterotopic Ossification
Durovic et al. (2009) randomly assigned 29 SCI patients to a control group or intervention group. Both received range of motion and exercise therapy; however, only the intervention group received PLIMF therapy an average of seven weeks post injury for four weeks. The study showed no incidence of HO in the treatment group yet a 33% incidence in the control group (p<0.04).

**Conclusion**

There is Level Ib evidence (from one RCT; Durovic et al. 2009) that Pulse Low Intensity Electromagnetic Field therapy is an effective prophylaxis of HO post SCI.

Pulse low intensity electromagnetic field therapy is effective in preventing heterotopic ossification post spinal cord injury.

### 5.5 Radiation Therapy

Radiation therapy or radiotherapy, which is the use of ionizing radiation for therapeutic ends, has been proposed as a possible adjunct treatment for HO.

**Table 6 Radiation Therapy for Treatment of Heterotopic Ossification**

<table>
<thead>
<tr>
<th>Author Year Country</th>
<th>Research Design Score</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Honore et al., 2020 France Case Control N=95</td>
<td><strong>Population:</strong> Case Group (n=33; SCI=11, traumatic head injury=8); Mean age: 24.2 yr; Gender: males=19, females=0; Level of injury: cervical=3, thoracic=8, lumber=0; Severity of injury: complete=9, incomplete=2; Mean time since injury: 12.6 mo; **Control Group (n=76; SCI=44, traumatic head injury=32); Mean Age: 25.3 yr; Gender: males=76, females=0; Level of injury: cervical=11, thoracic=30, lumber=2; Severity of injury: complete=32, incomplete=12; Mean time since injury: 18 mo.</td>
<td><strong>Intervention:</strong> The case group underwent HO excision and received perioperative radiotherapy on the operated area. For the</td>
<td>1. Symptomatic recurrence occurred in 10.5% of the case patients (n=2). 2. Almost half of case patients (n=9) developed complications (due to postoperative sepsis) after surgical excision and radiotherapy, requiring surgical revision. 3. Symptomatic recurrence occurred in 5.3% of the control patients (n=4). 4. Almost one-third of control patients (n=23) developed complications after surgical excision, and 21% (n=6) required surgical revision due to postoperative sepsis.</td>
</tr>
</tbody>
</table>
majority of case patients, the radiotherapy involved a single preoperative session (at a dose of 7.5 Gy, with 15 or 18 MV X-ray photons) carried out on the day before surgery. The control group underwent HO excision only. Each patient was paired with four control patients.

Outcome Measures: Primary Outcome Measure: recurrence of heterotopic ossification; Secondary Outcome Measures: postoperative complications (i.e., sepsis that required surgical revision).

5. There was no difference between the odds ratios (OR) for recurrence for each group (OR case group=0.63, OR spinal cord injury subgroup=0.45 and OR head injury subgroup=1.04).

6. The rate of sepsis requiring surgical revision was significantly higher in the case group (p <0.05).

**Museler et al., 2017 Germany Case Series N=244**

population: Mean age: 46.4 yr; Gender: males=207, females=37; Severity of injury: AIS: A=220, B =8, C=12, D=4.

Intervention: Single-dose radiation therapy at the hip for HO. Mean time of treatment was 4.9 days. Treatment was administered with either 15 MV or 6 MV.

Outcome Measures: HO recurrence, side effect due to radiation.

1. Of the 244 patients, 13 experienced recurrence of HO. All 13 patients initially experienced HO in both hips. Of the 444 initial cases of HO, there were 26 instances of recurrence.

2. No patients experienced negative side-effects as a result of radiation treatment.

**Sautter-Bihl et al. 2001 Germany Case Series N=52**

Population: Mean age: 33 yr; Gender: males=44, females=8;

Intervention: Patients received a single dose of radiotherapy 2-10Gy through a linear accelerator at 6-8 MV photons.

Outcome Measures: Efficacy, Brooker classification, adverse effects.

1. Prevention of HO was seen in 72% of (41 primarily treated, 9 resected) joints.

2. Radiotherapy treatment did not result in a regression of the Brooker score in any patient.

3. An increase in two Brooker score grades was seen in two joints (1 knee, 1 hip)

4. No adverse effects due to therapy occurred.

5. 16 of 32 hips treated only with radiotherapy (50%) did not show any abnormalities on follow-up.

6. No progression of HO was noted in 30/36 subjects (83%).

7. Re-ossification after therapy, which led to a decrease in joint mobility was noted in three subjects.

**Sautter-Bihl et al. 2000 Germany Case Series N=36**

Population: Age range: 17-59 yr; Gender: males=32, females=4; Follow-up range: 4-98mo.

Intervention: 25/36 subjects received 10 Gy radiotherapy in fraction of 2-2.5 Gy, while four patients received higher doses. In phase 2 seven subjects received a single does of irradiation with 8Gy. In total, 46 joints were irradiated.

1. No statistically significant results were reported.

2. 16 of the 32 hips treated with radiotherapy only did not show any abnormalities on follow-up.

3. No progression of HO was noted in 30/36 subjects.

4. Re-ossification after therapy, which led to a decrease in joint mobility was noted in three subjects.
Sautter-Bihl et al. (2000) studied 36 patients with HO of whom 27 patients (32 joints) received radiotherapy when ossification was minimal. 11 patients (13 joints) had obvious ossifications, which had to be resected. Post-op radiotherapy was performed 24-36 hours post-operatively. Two patients received radiotherapy both before and after surgery. Mean duration of follow-up was 23.6 months. 30 of the 36 irradiated patients showed no progression of HO. In three patients, reossification after therapy resulted in a moderate decrease in joint mobility.

In the follow-up case series by Sautter-Bihl et al. (2001), the authors examined the effectiveness of radiotherapy administered to 52 SCI patients. Radiotherapy effectively prevented primary and secondary HO post-surgical excision in 71% of patients. However, treatment did not result in regression of HO once developed, as measured by the Brooker scale. Two joints increased in Brooker score, although neither of them developed any functional impairment. Another case series by Museler et al. (2017) used either 15 MV or 6 MV radiotherapy to target HO at the hip in 244 patients. Recurrence of HO was found to be very low (5.3%), and of those that experienced recurrence HO was initially present in both hips.

In a case control study by Honore et al., (2020), patients with SCI and traumatic head injury underwent either excision and radiotherapy before surgery (at a dose of 7.5 Gy, with 15 or 18 MV X-ray photons; case group) or excision only (control group). The results revealed no differences between the odds ratios for HO recurrence between the case group and the control group. In addition, the case group patients were found to be significantly more likely to develop sepsis after surgical excision requiring surgical revision, compared to the control group patients. Based on these findings, the authors concluded that radiotherapy should not be combined with surgery in patients with hip HO undergoing excision.

A case study by Cramarossa et al. (2013) reported on the use of radiation therapy on a patient who had previously experienced an SCI at the C5-C6 level and had been diagnosed with dysphagia due to HO-induced osteophytes. One day after surgical intervention, which involved anterior cervical decompression and drilling of the osteophytes, the patient received a single treatment of radiation at 8 Gy. At follow-up, the patient reported that they were not experiencing any recurrence of dysphagic symptoms. The authors add that radiation should only be considered for patients at high risk of HO due to the risk of creating a radiotherapy-induced malignancy and that an expansion of the literature is required to better assist treatment decisions.

**Conclusion**

*There is level 3 evidence from one case control study (Honore et al., 2020) that combining radiotherapy with surgery in patients with hip HO undergoing excision may not prevent HO recurrence and may be associated with an increased risk of postoperative sepsis.*
There is moderate Level 4 evidence (from three case series studies; Sautter-Bihl et al. 2000; Sautter-Bihl et al. 2001; Museler et al. 2017) that radiotherapy reduces the progression and recurrence of heterotopic ossification.

There is conflicting evidence on whether radiotherapy can reduce the progression and recurrence of heterotopic ossification.

5.6 Surgical Resection

Surgical resection of HO post SCI is a well-established treatment but is still somewhat controversial.

Table 7 Surgical Resection for Treatment of Heterotopic Ossification

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>Research Design</th>
<th>Score</th>
<th>Method</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hollenberg &amp; Mesfin, 2020 USA Case Control N=28</td>
<td>Population: SCI with OPLL Group (n=12): Mean age: 59.7 yr; Gender: males=6, females=6; Level of injury: cervical=12; CM with OPLL Group (n=16): Mean age: 55.4 yr; Gender: males=7, females=9; Level of injury: NA. Intervention: A retrospective chart review was performed for all patients who underwent surgical management for Ossification of the Posterior Longitudinal Ligament (OPLL) OPLL in an academic medical center between November 2006 and July 2019. Patients were categorized into 1 of 2 groups and compared on the basis of their initial presentation: 1) SCI with OPLL or 2) cervical myelopathy (CM) with OPLL. Outcome Measures: Surgical approach, levels fused/decompressed, estimated blood loss (EBL), postoperative hospital length of stay, surgical complications, American Spinal Injury Association (ASIA) motor score (0-100) and impairment scale.</td>
<td></td>
<td>1. The most common type of OPLL in both groups was segmental (21.75%). 2. The average levels fused/decompressed (p=0.0176), estimated blood loss (p=0.0204), and postoperative length of stay (p=0.0003) were all significantly higher in the SCI with OPLL group. 3. There were significantly more anterior-only surgical approaches performed in the CM with OPLL group (p=0.0159). 4. The motor score at admission (P=0.0005) and at latest follow-up (p=0.0003) for the SCI with OPLL group was significantly lower than the CM with OPLL group.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al., 2017 United States Case Series N=8</td>
<td>Population: Mean age: 58.25 yr; Gender: males=6; Severity of injury: AIS: A=4, B=3, D=1. Intervention: Surgical resection, two patients had additional prophylactic radiation, and one had pharmacological prophylaxis. Outcome Measures: Mortality, healed surgical site.</td>
<td></td>
<td>1. One of the eight patients died at 9mo post-op. 2. Six of the eight patients treated for HO healed well, while one had ongoing healing at 6 mo post-op.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>Research Design</td>
<td>Score</td>
<td>Total Sample Size</td>
<td>Methods</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-----------------</td>
<td>-------</td>
<td>-------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Genet et al. 2011</td>
<td>France</td>
<td>Case Series</td>
<td>86</td>
<td>N=86</td>
<td><strong>Population:</strong> Mean age: 27.3yr; Gender: males=70, females=16; Mean time since injury: 13.1mo. <strong>Intervention:</strong> Charts of patients who underwent surgical resection for HO were examined. <strong>Outcome Measures:</strong> Recurrence of HO.</td>
</tr>
<tr>
<td>Schuetz et al. 2005</td>
<td>Switzerland</td>
<td>Case Series</td>
<td>7</td>
<td>N=7</td>
<td><strong>Population:</strong> Age range: 47-68 yr; Gender: males=7; Injury etiology: SCI=7; Level of injury: thoracic=1, tetraplegia=2. <strong>Intervention:</strong> All patients underwent excision-surgery for removal of HO. Pamidronate was administered IV peri-and post-op, starting at a dose level of 120 mg for 1st 12 hr and gradually increasing for a total of 6-14 days. <strong>Outcome Measures:</strong> Prevalence of HO.</td>
</tr>
<tr>
<td>Meiners et al. 1997</td>
<td>Germany</td>
<td>Case Series</td>
<td>31(43 hips); N_final=29 (41 hips)</td>
<td>N=31</td>
<td><strong>Population:</strong> Mean age: 37.87 yr; Gender: males=28, females=3; Level of injury: paraplegia=19, tetraplegia=10; Severity of injury: complete 22, incomplete 7; Time since injury range: 17-298 mo; Hip side: L=16, R=23. <strong>Intervention:</strong> Resection of HO of the hip via ventral approach. Post-operation: wk 1irradiation of hip with a linear accelerator; Day 15–passive movement exercises implemented. <strong>Outcome Measures:</strong> Range of motion (flexion and extension) pre-, post-, intra-operatively and at follow-up.</td>
</tr>
<tr>
<td>Garland &amp; Orwin 1989</td>
<td>USA</td>
<td>Case Series</td>
<td>19</td>
<td>N=19</td>
<td><strong>Population:</strong> Mean age=22.5yr; Level of injury: paraplegia=8, tetraplegia=11; Severity of injury: complete=12, incomplete=7. <strong>Intervention:</strong> Records of those who underwent hip resection for HO between 1970 and 1985 were reviewed. <strong>Outcome Measures:</strong> Range of motion, recurrence rate, and adverse effects.</td>
</tr>
<tr>
<td>Subbarao et al. 1987</td>
<td>USA</td>
<td>Case Series</td>
<td>19</td>
<td>N=19</td>
<td><strong>Population:</strong> Age range: 29-41yr; Time since injury range: 18–197 mo.</td>
</tr>
</tbody>
</table>
A case control study by Hollenberg and Mesfin (2020) assessed the influence of traumatic SCI on the operative management of cervical ossification of the posterior longitudinal ligament (OPLL). A chart review of the medical records of 12 individuals with SCI and 16 individuals with cervical myelopathy (CM) who underwent surgical management for OPLL was performed. It was found that while most patients in both the SCI with OPLL group and the CM with OPLL group showed neurologic improvement after the surgery, patients with SCI had worse postoperative neurologic motor scores compared to those with CM.

The timing for surgical resection continues to split consensus; surgery once the HO has completely matured is considered the usual course of action. Despite that, there are growing calls for surgery to be delayed until the patient has primarily recovered from their SCI (Gurcan et al. 2013). However, a delay in excision has been found to lead to a series of negative events such as increased risk of fracture, ankylosis, bone loss, and intra-articular lesions (Genêt et al. 2015).

Meiners et al. (1997) reported a case series of 29 individuals (10 with quadriplegia and 19 with paraplegia) who underwent HO resection at the hip followed by irradiation and eventually passive range of motion exercises. Mean hip range of motion increased from 2195° pre-operatively to 94.5° intra-operatively and 82.68° at four year (mean) follow-up. Garland and Orwin (1989) also reported that HO excision improved range of motion (ROM) in 19 individuals with SCI. They found that the largest gain of function occurred intra-operatively followed by a large loss of function within the first six months. At final follow-up (six years post-surgery), three of 24 hip joints where HO was surgically excised had similar or less ROM when compared with preoperative ROM, 15 improved between 10° and 39°, while six showed greater than 40° improvement. Yang et al. (2017) found similar rates of improvement following HO resection. In a case series with eight patients that underwent surgical resection, six healed well, one patient had ongoing healing at 6 months due to a post-operative infection, and one patient died (Yang et al., 2017).

Some studies stress that surgical resection must be followed by prophylaxis (radiation therapy, NSAID or bisphosphonates) due to high recurrence rates after surgery alone. A case study by Gurcan et al. (2013) investigated the use of surgical resection in a patient with total ankylosis of the right hip following a T8-T9 fracture.
Upon excision of the cephalad mass, the patient’s hip could be flexed to 100° and abducted to 30° on the operating table, indicating a successful operation. Post-operatively, the patient completed passive movements of the hip, and was treated with a single dose of radiation (eight Gy) and a prescription for indomethacin with a dosage of 150mg a day. At 12-month follow-up post-surgery, improved range of motion in the hip was preserved with no recurrence of HO or ankylosis.

The effectiveness of surgical excision followed by bisphosphonates was examined in two case series (Schuetz et al. 2005; Subbarao et al. 1987). Etidronate treatment post-surgical excision showed that patients were able to function independently in a wheelchair; however, they had severe restrictions in their range of motion (Subbarao et al. 1987). Surgical excision supplemented with pamidronate treatment resulted in no recurrence of HO post-surgery (Schuetz et al. 2005).

Genêt et al. (2015) conducted a review of the literature regarding recurrence rates of HO after surgical excision. A finding of concern was the lack of consensus towards the classification of HO and risk of recurrence. While some studies have attempted this, the authors point out that these are based on observation only and are merely descriptive. Moreover, the review was not able to clarify ideal timing for surgical resection, in part due to disparate rates of recurrence post-surgery. A prominent issue of HO recurrence is the definition of recurrence. Genêt et al. (2015) highlight that some patients are not deemed to have had recurring HO post-surgery if the patient’s function is not impaired. Furthermore, pre- and post-surgical care is not standardized; early rehabilitation (including limb mobilization) is often delayed due to inflammation and treated with NSAIDs instead.

**Conclusion**

There is level 3 evidence (from one case control study; Hollenberg & Mesfin, 2020) that patients with SCI complicated by OPLL may have worse preoperative and postoperative motor function compared to patients with CM and OPLL.

There is level 4 evidence (from four case series; Garland & Orwin 1989; Meiners et al. 1997; Genet et al. 2011; Yang et al. 2017) that resection of HO about the hip post SCI can dramatically improve restricted hip range of motion; however, postsurgical recurrence and complications are a concern for this treatment.

There is Level 4 evidence (from one case series; Schuetz et al. 2005) that surgical resection combined with pamidronate treatment effectively halts secondary HO progression.

There is level 4 evidence (from one case series; Subbarao et al. 1987) that surgical resection combined with etidronate treatment improves independence with wheelchair use but contributes to reduced range of motion.
Patients with SCI complicated by OPLL may have worse preoperative and postoperative motor function compared to patients with CM and OPLL.

Surgical resection of heterotopic ossification can improve hip range of motion but it may reoccur in a large number of individuals.

Surgical resection and pamidronate treatment halts secondary heterotopic ossification progression.
6.0 Summary

There is strong Level 1a evidence (from two RCTs; Banovac et al. 2001; Banovac et al. 2004) and level 3 evidence (from one case control study; Zakrasek et al., 2019) that non-steroidal anti-inflammatory medications can reduce the incidence of heterotopic ossification when administered early after a spinal cord injury.

There is Level 5 evidence (from one observational study; Buschbacher et al. 1992) that Warfarin inhibits the development of heterotopic ossification post spinal cord injury.

There is conflicting Level 2 evidence (from two prospective controlled trials; Banovac et al. 1993; Banovac et al. 1997) and Level 4 evidence (from one case series; Branovac 2000) that Etidronate can stop the progression of heterotopic ossification once the diagnosis is made and prevent further HO sites.

There is level 2 evidence (from one prospective controlled trial; Ploumis et al. 2015) that Alendronate does not inhibit the development of heterotopic ossification and in fact may contribute to the development of contractures.

There is Level 2 evidence (from one prospective controlled trial; Banovac et al. 1997) that Etidronate is not effective once radiographs are positive for HO.

There is Level 4 evidence (from one case series; Schuetz et al. 2005) that pamidronate effectively halts secondary HO progression after surgical resection of HO.

There is Level 1b evidence (from one RCT; Durovic et al. 2009) that Pulse Low Intensity Electromagnetic Field therapy is an effective prophylaxis of HO post SCI

There is level 3 evidence from one case control study (Honore et al., 2020) that combining radiotherapy with surgery in patients with hip HO undergoing excision may not prevent HO recurrence and may be associated with an increased risk of postoperative sepsis.

There is moderate Level 4 evidence (from three case series studies; Sautter-Bihl et al. 2000; Sautter-Bihl et al. 2001; Museler et al. 2017) that radiotherapy reduces the progression and recurrence of heterotopic ossification.

There is level 3 evidence (from one case control study; Hollenberg & Mesfin, 2020) that patients with SCI complicated by OPLL may have worse preoperative and postoperative motor function compared to patients with CM and OPLL.

There is level 4 evidence (from four case series; Genet et al. 2011; Garland & Orwin 1989; Meiners et al. 1997; Yang et al. 2017) that resection of HO about the hip post SCI can dramatically improve restricted hip range of motion; however, postsurgical recurrence and complications are a concern for this treatment.
There is Level 4 evidence (from one case series; Schuetz et al. 2005) that surgical resection combined with pamidronate treatment effectively halts secondary HO progression.

There is level 4 evidence (from one case series; Subbarao et al. 1987) that surgical resection combined with etidronate treatment improves independence with wheelchair use but contributes to reduced range of motion.
7.0 References


Freed J H, Hahn H, Menter R, Dillon T. The use of the three-phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of didronel therapy. *Paraplegia* 1982;208-16.


Povoroznyuk V, Bystrytska M, Balatska N. May P1NP level be the early markers of the heterotopic ossification in patients with spinal cord injury? *Calcified Tissue International*. 2017;100(1 Supplement 1).


Winkler S, Niedermair T, Fuchtmeier B, Grifka J, Grassel S, Anders S, Heers G. The impact of hypoxia on mesenchymal progenitor cells of human skeletal tissue in


**Abbreviations**

ALP  Alkaline Phosphate Level  
COP  Circular Osteogenic Precursor Cells  
CPK  Creatine Phosphokinase  
CT  Computed Tomography  
HO  Heterotopic Ossification  
MRI  Magnetic Resonance Imaging  
PLIMF  Pulse Low Intensity Electromagnetic Field  
SCI  Spinal Cord Injury